Madrigal Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapeutics for metabolic dysfunction-associated steatohepatitis (MASH). Its primary product, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta (THR-β) agonist approved by the U.S. FDA and the European Commission for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis. The company launched Rezdiffra in the United States in April 2024 and in Germany in September 2025. Madrigal is currently evaluating Rezdiffra in patients with compensated MASH cirrhosis in the Phase 3 MAESTRO-NASH OUTCOMES trial. The company’s pipeline includes MGL-2086, an oral glucagon-like peptide-1 (GLP-1) receptor agonist licensed from CSPC Pharmaceutical Group Limited; ervogastat, an oral diacylglycerol O-acyltransferase 2 (DGAT2) inhibitor; and six small interfering RNA (siRNA) programs licensed from Ribocure. Madrigal was incorporated in 2011 and went public in 2016.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage madrigalpharma.com
Sector Healthcare IR page ir.madrigalpharma.com/news-releases
Tags
hepatology, metabolic dysfunction-associated steatohepatitis, thyroid hormone receptor beta agonists, glp-1 receptor agonists, sirna therapeutics, liver fibrosis, oral small molecules, gene silencing, Rezdiffra, resmetirom, MGL-2086, ervogastat, MAESTRO-NASH OUTCOMES, MAESTRO-NAFLD-1, CSPC Pharmaceutical Group Limited, Ribocure Pharmaceuticals AB, Suzhou Ribo Life Science Co. Ltd.
Press page —

Metrics

Valuation  
Market cap $ 9.102B
Market cap (USD) $ 9.102B
P/E -65.77
PEG —
P/BV 14.52
P/S 6.37
P/OCF -57.97
P/FCF -53.97
Dividend yield —
Turnover / mcap —
Returns  
ROE -42.5%
ROI -30.6%
ROIC -23.9%
Profit margin -30.1%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 54.4%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 51
Quality score -40.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006
Revenue 958.403M 180.133M 0 0 0 0 0 — — — — — — — — — — — — —
Net profit -288.284M -465.892M -373.63M -295.35M -241.846M -202.244M -83.948M -32.811M -31.154M -26.388M -68.671M -86.161M -90.192M -62.79M -47.38M -37.467M 79.088M -92.618M -63.495M -57.27M
Free cash flow -190.02M -457.034M -325.709M -225.074M -184.126M -157.895M -41.796M -25.529M -22.442M -17.611M -71.502M -79.069M -78.18M -54.64M -47.99M -38.335M -27.264M -40.123M 24.872M -54.565M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006
Share price 582.34 308.57 231.38 290.25 84.74 111.17 91.11 112.72 91.79 14.9 — — — — — — — — — —
Price performance 12m 0.89 0.33 -0.2 2.43 -0.24 0.22 -0.19 0.23 5.16 — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — — — — — 0.00 53.8M 134M
↳ YoY growth +149.9%
Borrowings, non-current (USD) — — — — — 0.00 49.3M 115M 118M 340M
Lease liabilities (USD) — — — 676,000 786,000 797,000 602,000 1.71M 2M 7.75M
Cash and deposits (USD) 19.1M 149M 57.4M 46.7M 54M 36.3M 332M 99.9M 100M 199M
Intangible assets (USD) — — — — — — — 0.00 4.73M 7.38M
Right-of-use assets (USD) — — — 675,000 785,000 797,000 602,000 1.71M 2.4M 4.94M
Net debt (borrowings + leases - cash) (USD) — — — — — -35.5M -282M 17.3M 19.6M 149M
Cash flow detail
Operating cash flow (USD) -17.6M -22.3M -25.5M -41.6M -158M -184M -225M -324M -456M -190M
Purchases of property, plant and equipment (USD) -3,080 -125,000 -22,000 -172,000 -334,000 -209,000 -217,000 -1.48M -1.46M -467,000
Purchases of intangible assets (USD) — — — — — — 0.00 0.00 -5M -3M
Change in receivables (cash effect) (USD) 7,332 — — — — — 0.00 0.00 -53.8M -80.7M
Change in inventories (cash effect) (USD) — — — — — — 0.00 0.00 -34.1M -37M
Share-based compensation (USD) 7.93M 3.25M 13.5M 22.8M 20.7M 26.9M 31.6M 49.7M 79.9M 98.1M
Operating cash flow before change in receivables (USD) -17.6M — — — — — -225M -324M -402M -109M
Free cash flow (OCF - PPE - intangibles) (USD) -17.6M -22.4M -25.5M -41.8M -158M -184M -225M -326M -462M -193M
Income detail
Research and development expense (USD) 15.9M 24.4M 25.4M 72.3M 185M 205M 245M 272M 237M 389M
↳ 5y CAGR -17.4% -13.2% -18.8% +1.2% +27.8% +66.7% +58.7% +60.7% +26.8% +16.0%
Total comprehensive income (USD) -26.4M -31.2M -33.1M -83.4M -202M -242M -295M -373M -466M -288M
Comprehensive income to owners (USD) -26.4M -31.2M -33.1M -83.4M -202M -242M -295M -373M -466M -288M
Provision for credit losses (USD) — — — — — — — — 0.00 0.00
Credit cost ratio (credit losses / average receivables) (%) — — — — — — — — 0.0% 0.0%
Reported Mar 31, 2017 Mar 13, 2018 Feb 27, 2019 Feb 26, 2020 Feb 25, 2021 Aug 4, 2022 Feb 26, 2025 Feb 26, 2025 Feb 26, 2025 Feb 19, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 5, 2026

PDF Version

  • In real-world studies, up to 93% of patients experienced improvement or stabilization in liver stiffness with ultrasound elastography, with many patients moving into lower liver stiffness categories one year after treatment initiation

  • Treatment persistence studies showed up to 72% of patients remained on Rezdiffra® (resmetirom) at one year, with high adherence

  • Improvements in liver stiffness and other measures of liver health were observed regardless of concomitant GLP-1 use, with up to 53% of patients receiving GLP-1 therapies alongside Rezdiffra

  • Safety findings were consistent with the established safety profile of Rezdiffra observed in clinical trials

CONSHOHOCKEN, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced results from multiple real-world studies of Rezdiffra presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place Nov. 5–9 in Denver.

The studies provide new insights into clinical outcomes and treatment patterns among patients with MASH receiving Rezdiffra in routine U.S. clinical practice, including those with cardiometabolic comorbidities. Across multiple independent real-world data sources, patients achieved meaningful improvements (based on a 25% threshold) or stabilization in liver stiffness measurements, a noninvasive marker associated with liver fibrosis, approximately one year after treatment initiation. Additional analyses demonstrated improvements in transaminase levels, liver fat and cardiometabolic markers, alongside encouraging trends in treatment persistence and adherence.

"These new data represent an important expansion of the real-world evidence supporting Rezdiffra as a foundational therapy for patients with MASH," said David Soergel, M.D., Chief Medical Officer of Madrigal. "Across multiple studies and diverse patient populations, we are seeing robust improvements in noninvasive measures of liver health consistent with the positive results observed in the pivotal Phase 3 trial of Rezdiffra. The findings also provide encouraging evidence that most patients are staying on therapy over time. Together, these results reinforce the strong real-world effectiveness, safety and tolerability profile of Rezdiffra, and provide valuable insight into how the medication is being used in everyday clinical practice.”

Real-world studies demonstrate consistent improvements in liver stiffness at one year

Several studies presented at AASLD evaluated changes in liver stiffness measurements (LSM) using ultrasound elastography, which is increasingly used in clinical practice to assess liver fibrosis and monitor patients with MASH. Across studies, approximately 37% to 55% of patients with paired measurements achieved a ≥25% improvement in liver stiffness after approximately one year; most improved or remained stable.1-3, 9

Key findings included:

  • Truveta Data: Among 150 patients with paired LSMs, 55% achieved a ≥25% improvement in liver stiffness and 48.0% achieved a ≥30% improvement at 12 months. Overall, 93% improved or remained stable, and 67% transitioned to a lower pre-defined liver stiffness range.1

  • Trio Health Data: Among 195 patients with paired LSMs, 45% achieved a ≥25% improvement and 38% achieved a ≥30% improvement at 12 months; 88% improved or remained stable. Separately, 44% of 347 patients with documented fibrosis stages improved by at least one stage.2

  • Gastro Health/Latica: Among 112 patients with paired LSMs, 47% achieved a ≥25% improvement and approximately 38% achieved a ≥30% improvement at follow-up; approximately 89% improved or remained stable using the 25% threshold. Moreover, 32 of 46 patients starting between 10 and <20 kPa moved below 10 kPa at follow-up.³

  • Methodist Dallas Medical Center: Among 35 patients with paired LSMs, 37% achieved a ≥25% improvement and 26% achieved a ≥30% improvement at 12 months; 83% improved or remained stable.⁹

“Not every medicine delivers the same results in real-world clinical practice that we see in carefully controlled clinical trials, particularly when treating a complex, chronic disease like MASH,” said Parvez Mantry, M.D., at The Liver Institute at Methodist Dallas Medical Center. “What makes these findings so encouraging is the remarkable consistency of improvement we're seeing across multiple real-world studies of Rezdiffra, involving different patient populations and clinical settings. For physicians treating MASH, this growing body of evidence provides important reassurance that the benefits observed in these trials are translating into everyday patient care.”

Improvements observed across diverse patient populations and measures of liver health

Additional analyses demonstrated consistent improvements in liver-related and cardiometabolic biomarkers among patients initiating Rezdiffra, including those with comorbidities such as type 2 diabetes, obesity and cardiovascular disease and those receiving concomitant GLP-1 receptor agonists or statins.

A subgroup analysis from the Truveta Data of 2,488 patients found statistically significant improvements in mean liver stiffness and liver fat measurements across subgroups defined by diabetes, obesity, GLP-1 receptor agonist use and statin use. Across these subgroups, approximately 89% to 98% of patients with paired measurements experienced improvement (based on 25% threshold) or stabilization in liver stiffness.4

The broader Truveta Data analysis also demonstrated statistically significant reductions compared to baseline in markers of liver injury and cardiometabolic health at 12 months, including:

  • Mean ALT decreased by 16.2 U/L.

  • Mean liver stiffness decreased by 2.5 kPa.

  • Mean LDL cholesterol decreased by 15.5 mg/dL.

  • Mean triglycerides decreased by 41.0 mg/dL.

Similar trends were observed in the Trio Health study, where 54% of patients achieved a clinically meaningful reduction in liver fat, measured by controlled attenuation parameter (CAP, based on >40 dB/m), and 48% achieved a reduction in ALT of at least 20% from baseline.2

A separate real-world analysis using Optum Market Clarity data also found statistically significant reductions in liver enzymes and select cardiometabolic measures at 12 months, providing additional evidence of consistent trends across different healthcare datasets.5

Real-world studies demonstrate encouraging treatment persistence and adherence

Three additional studies evaluated Rezdiffra treatment adherence and persistence using pharmacy and administrative claims data;6-8 one retrospective cohort analysis included 11,469 patients from a large U.S. specialty and retail pharmacies database (CVS Healthspire database).

Across these analyses, up to 72% of patients remained persistent with Rezdiffra at 12 months using a 60-day treatment-gap definition. Persistence at six months was up to 89%.

The studies provide early benchmarks for understanding long-term treatment patterns in routine clinical practice. Most patients remained on treatment at one year, and adherence among patients continuing therapy was high.

Safety findings were generally consistent with the established safety profile of Rezdiffra observed in clinical trials. In a real-world analysis evaluating treatment-related adverse events, reported events were infrequent, with 11% of patients experiencing ≥1 adverse event. The most frequently reported events were diarrhea (7%), nausea (4%), pruritus (2%), vomiting (2%) and fatigue (≤1%).³

About MASH Metabolic dysfunction-associated steatohepatitis (MASH) is a serious liver disease that can progress to cirrhosis, liver failure, liver cancer, the need for liver transplantation and premature mortality. MASH is the leading cause of liver transplantation in women and the second leading cause of all liver transplantation in the U.S., and the fastest-growing indication for liver transplantation in Europe.

Once patients progress to MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), the risk of adverse liver outcomes increases dramatically: these patients have a 10 to 17 times higher risk of liver-related mortality as compared to patients without fibrosis.

Patients with MASH who progress to cirrhosis face a 42 times higher risk of liver-related mortality, underscoring the need to treat MASH before complications of cirrhosis develop. MASH is also an independent driver of cardiovascular disease, the leading cause of mortality for patients.

As disease awareness improves and disease prevalence increases, the number of diagnosed patients F2 to F4c MASH is growing.

About Rezdiffra What is Rezdiffra? Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver.

This indication is approved based on improvement of MASH and liver scarring (fibrosis). There are ongoing studies to confirm the clinical benefit of Rezdiffra.

Before you take Rezdiffra, tell your healthcare provider about all of your medical conditions, including if you:

  • have any liver problems other than MASH.

  • have gallbladder problems or have been told you have gallbladder problems, including gallstones.

  • are pregnant or plan to become pregnant. It is not known if Rezdiffra will harm your unborn baby.

  • A pregnancy safety study for women who take Rezdiffra during pregnancy collects information about the health of you and your baby. You or your healthcare provider can report your pregnancy by visiting https://pregnancyregistry.madrigalpharma.com/ or calling 1-800-905-0324.

  • are breastfeeding or plan to breastfeed. It is not known if Rezdiffra passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take Rezdiffra.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.

  • Rezdiffra and other medicines may affect each other, causing side effects. Rezdiffra may affect the way other medicines work, and other medicines may affect how Rezdiffra works.

  • Especially tell your healthcare provider if you take medicines that contain gemfibrozil to help lower your triglycerides, because Rezdiffra is not recommended in patients taking these medicines.

  • Tell your healthcare provider if you are taking medicines such as clopidogrel to thin your blood or statin medicines to help lower your cholesterol.

  • Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

What are the possible side effects of Rezdiffra? Rezdiffra may cause serious side effects, including:

  • liver injury (hepatotoxicity). Stop taking Rezdiffra and call your healthcare provider right away if you develop the following signs or symptoms of hepatotoxicity: tiredness, nausea, vomiting, fever, rash, your skin or the white part of your eyes turns yellow (jaundice) or stomach pain/tenderness.

  • gallbladder problems. Gallbladder problems such as gallstones, or inflammation of the gallbladder, or inflammation of the pancreas from gallstones can occur with MASH and may occur if you take Rezdiffra. Call your healthcare provider right away if you develop any signs or symptoms of these conditions including nausea, vomiting, fever, or pain in your stomach area (abdomen) that is severe and will not go away. The pain may be felt going from your abdomen to your back and the pain may happen with or without vomiting.

  • The most common side effects of Rezdiffra include: diarrhea, nausea, itching, stomach pain, vomiting, dizziness and constipation.

These are not all the possible side effects of Rezdiffra. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Madrigal at 1-800-905-0324.

Please see the full Prescribing Information, including Patient Information, for Rezdiffra.

About Madrigal Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com and follow us on LinkedIn.

Forward-Looking Statements This press release includes “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are based on Madrigal’s beliefs and assumptions on information currently available to it and are subject to a number of risks and uncertainties including, but not limited to: the assumptions underlying the forward-looking statements; Madrigal’s ability to successfully commercialize Rezdiffra in the U.S. and Europe; conditions imposed by regulators relating to the scope and design of Madrigal’s clinical trials; risks related to obtaining and maintaining regulatory approvals, including, but not limited to, potential regulatory delays or rejections; Madrigal’s history of operating losses and the possibility that it may never achieve or maintain consistent profitability; risks associated with meeting the objectives of Madrigal’s clinical trials, including, but not limited to Madrigal’s ability to achieve enrollment objectives concerning patient numbers (including an adequate safety database), outcomes objectives and/or timing objectives for Madrigal’s trials; any delays or failures in enrollment, and the occurrence of adverse safety events; risks related to the effects of Rezdiffra’s (resmetirom’s) mechanism of action or of any other product candidate; market demand for and acceptance of Rezdiffra; Madrigal’s ability to service indebtedness and otherwise comply with debt covenants; outcomes or trends from competitors; future topline data timing or results; Madrigal’s ability to prevent and/or mitigate cyber-attacks; Madrigal’s ability to protect its intellectual property rights; the uncertainties inherent in clinical testing; uncertainties concerning analyses or assessments outside of a controlled clinical trial; and changes in laws and regulations applicable to Madrigal’s business and its ability to comply with such laws and regulations. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Madrigal undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Please refer to Madrigal’s submissions filed with the U.S. Securities and Exchange Commission (SEC) for more detailed information regarding these risks and uncertainties and other factors that may cause actual results to differ materially from those expressed or implied. Madrigal specifically discusses these risks and uncertainties in greater detail in the sections appearing in Part I, Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2025, and as updated from time to time by Madrigal’s other filings with the SEC.

Madrigal may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Madrigal’s website in addition to following its press releases, filings with the SEC, public conference calls, and webcasts.

Madrigal Pharmaceuticals, Rezdiffra**®** and associated logos are trademarks of Madrigal Pharmaceuticals, Inc.

Investor Contact Tina Ventura, [email protected]

Media Contact Krysta Pellegrino, [email protected]

References:

  1. Thapa S, Parrinello CM, Kim Y, O’Donnell JC, Martinez A. Twelve-month changes in laboratory- and imaging-based biomarkers in patients who have initiated resmetirom: a real-world retrospective cohort analysis using electronic health records. Poster 3477. Presented at AASLD The Liver Meeting; November 5–9, 2026; Denver, Colorado.

  2. Bansal M, Parrinello C, Lobo F, et al. Real-World Characteristics, Treatment Patterns, and Clinical Outcomes Among Patients with MASH Initiating Resmetirom. Poster 3508. Presented at AASLD The Liver Meeting; November 5–9, 2026; Denver, Colorado.

  3. Kim Y, O’Donnell JC, Fakhraei R, et al. A 12-month real-world assessment of clinical characteristics and biomarker changes following resmetirom initiation in patients with MASH: a descriptive cohort study using electronic medical records in the United States. Poster 3516. Presented at AASLD The Liver Meeting; November 5–9, 2026; Denver, Colorado.

  4. Martinez A, Thapa S, Parrinello CM, Kim Y, O’Donnell JC. Twelve-month changes in laboratory- and imaging-based biomarkers following resmetirom initiation: a real-world analysis across cardiometabolic and concomitant medication subgroups. Poster 3433. Presented at AASLD The Liver Meeting; November 5–9, 2026; Denver, Colorado.

  5. Bansal M, Burrell E, Gutierrez C, et al. Patient Characteristics and Changes in Liver Function Laboratory Tests Among Resmetirom Treated Patients in a Real-World MASH Population. Poster 3577. Presented at AASLD The Liver Meeting; November 5–9, 2026; Denver, Colorado.

  6. Fernandes J, Kumar R, Thomas SM, Thomas B, Atreja N, Lobo F. Real-World Medication Adherence and Persistence to Resmetirom in Patients with MASH. Poster 2530. Presented at AASLD The Liver Meeting; November 5–9, 2026; Denver, Colorado.

  7. Dixon R, Wang Z, Teng C, et al. Treatment Persistence Among Patients Prescribed Resmetirom in a US Claims-Based Cohort. Poster 3559. Presented at AASLD The Liver Meeting; November 5–9, 2026; Denver, Colorado.

  8. Lobo F, Han Y, Atreja N, Felber G, DeKoven M. Treatment Continuity with Resmetirom: A Real-World Study of Adherence and Persistence in Metabolic Dysfunction-Associated Steatohepatitis (MASH). Poster 3514. Presented at AASLD The Liver Meeting; November 5–9, 2026; Denver, Colorado.

  9. Sandhu J, Felber G, McKinley T, Parrinello C, Clark S, Lobo F, Zeng Z, Mantry P. Real-World Characteristics and Clinical Effectiveness Outcomes Among Patients with MASH Initiating Resmetirom. Poster 3481. Presented at AASLD The Liver Meeting; November 5–9, 2026; Denver, Colorado.

Primary Logo

close

You are now leaving madrigalpharma.com.

By clicking this link you will be redirected to a website that is neither owned nor controlled by Madrigal. Madrigal is not responsible for the content or services of this site.

Continue

Stay Here

close

November 3, 2026

PDF Version

  • Third-quarter 2026 Rezdiffra® (resmetirom) net sales of $431.3 million, representing year-over-year growth of 50%; achieved first quarter of profitability

  • Rezdiffra reaches a major milestone, achieving blockbuster status with year-to-date net sales of $1.1 billion

  • As of Sept. 30, 2026, more than 55,850 patients on Rezdiffra, nearly doubling from 3Q25, reflecting continued strong prescriber adoption and high patient demand

  • U.S. F2-F3 MASH market is accelerating, growing to more than 530,000 addressable patients through June 30, 2026, on track for more than 30% growth by YE26

  • Madrigal strengthens its leadership position in well-compensated MASH cirrhosis (F4c) with new MAESTRO-CSPH outcomes clinical trial; MAESTRO NASH OUTCOMES on track, data expected late 2027

  • Reports cash, cash equivalents, restricted cash and marketable securities of $961.8 million as of Sept. 30, 2026

  • Appointed John C. Reed, M.D., Ph.D., to Board of Directors

  • Company to host conference call today, Nov. 3, 2026, at 8 a.m. EST

CONSHOHOCKEN, Pa., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports third-quarter 2026 financial results and provides corporate updates.

Bill Sibold, Chief Executive Officer of Madrigal, stated: “Madrigal delivered another strong quarter, driven by continued Rezdiffra demand, deepening prescriber adoption and accelerating market growth. Rezdiffra surpassed $1 billion in year-to-date net sales, achieving blockbuster status less than three years after launch, and we are still early in a rapidly growing market. Our latest analysis shows the addressable U.S. F2-F3 market is on track to increase more than 30 percent by year-end 2026, reinforcing how quickly this category is developing and the significant runway ahead.”

Sibold continued: “Madrigal’s next major opportunity is in well-compensated cirrhosis, or F4c, an urgent unmet need for patients. Our objective in F4c is clear: be first and best. Our ongoing MAESTRO-NASH OUTCOMES trial positions us to deliver the first approved therapy to patients with this advanced stage of MASH. MAESTRO-CSPH is our new, Phase 3, practice-shaping trial that we expect will extend our competitive advantage and strengthen our long-term leadership in this rapidly growing market.”

Third Quarter 2026 and Recent Corporate Updates

  • Strengthens leadership in well-compensated MASH cirrhosis (F4c) with new MAESTRO-CSPH Phase 3 outcomes trial

  • Madrigal plans to initiate MAESTRO-CSPH, a second Phase 3 event-driven outcomes trial that builds on its ongoing MAESTRO-NASH OUTCOMES study. The trial is expected to enroll more than 2,000 F4c patients, with a population significantly enriched for clinically significant portal hypertension (CSPH). It is designed to generate the broadest dataset in F4c and support validation of noninvasive biomarkers for Rezdiffra and future pipeline programs. Trial initiation is expected in the first half of 2027, subject to regulatory discussions.

  • Madrigal to have strong presence at upcoming AASLD Liver Meeting

  • Madrigal will have a significant presence at the upcoming American Association for the Study of Liver Diseases (AASLD) Liver Meeting taking place Nov. 5-9 in Denver, CO. Resmetirom will be featured in more abstracts than any other MASH therapy at the conference. Eighteen Madrigal abstracts have been accepted, including 13 abstracts based on real-world evidence where the largest data set spans nearly 12,000 patients, underscoring the breadth of Madrigal’s evidence-generation program for Rezdiffra and MASH.

  • Journal of Hepatology publication demonstrates Rezdiffra’s consistent efficacy across common MASH genetic risk variants

  • Secondary analysis of the Phase 3 MAESTRO-NASH trial demonstrated Rezdiffra improved histology and MRI-PDFF across common genetic variants associated with MASH progression including PNPLA3, HSD17B13, TM6SF2, MTARC1 and MBOAT7, reinforcing Rezdiffra as a foundational treatment.

  • Appointed John C. Reed, M.D., Ph.D., to Madrigal’s Board of Directors

  • In August, Dr. John Reed was appointed to Madrigal’s Board of Directors. Currently Dr. Reed serves as Executive Vice President, Innovative Medicine, Research & Development at Johnson & Johnson where he leads research and development across oncology, immunology and neuroscience. He previously held executive leadership positions at both Sanofi and Roche.

Third**-Quarter 2026 Financial Results**

  • **Total Revenues:**Third-quarter 2026 net revenues were $431.3 million, an increase of 50% compared to $287.3 million in the comparable prior year period, driven by increased demand for Rezdiffra in the U.S. in 2026.

  • **Operating Expenses:**Third-quarter 2026 operating expenses were $375.3 million, inclusive of $38.9 million in non-cash stock-based compensation expense, compared to $401.2 million, inclusive of $26.3 million in non-cash stock-based compensation expense, in the comparable prior year period.

  • **Cost of Sales:**Third-quarter 2026 cost of sales was $37.8 million compared to $18.1 million in the comparable prior year period. The increase in cost of sales was primarily driven by higher royalties payable to Roche as a result of increased net sales of Rezdiffra in 2026.

  • **R&D Expenses:**Third-quarter 2026 R&D expenses were $71.8 million compared to $174.0 million in the comparable prior year period, both inclusive of non-cash stock-based compensation. The decrease in R&D expenses was primarily due to the one-time, upfront business development expense of $117.3 million in the comparable prior year period.

  • **SG&A Expenses:**Third-quarter 2026 SG&A expenses were $265.7 million compared to $209.1 million in the comparable prior year period, both inclusive of non-cash stock-based compensation. The increase in SG&A expenses was primarily due to continued investment in commercial activities for Rezdiffra, including headcount for the endocrinology field force expansion that began in the fourth quarter of 2025, and marketing efforts, including a direct-to-consumer (DTC) campaign.

  • **Net Income:**Third-quarter 2026 net income was $55.4 million, or $1.90 per basic share and $1.83 per diluted share, compared to a net loss of $114.2 million, or $4.01 per basic and diluted share, in the comparable prior year period.

  • **Cash, Cash Equivalents, Restricted Cash and Marketable Securities:**As of Sept. 30, 2026, Madrigal had cash, cash equivalents, restricted cash, and marketable securities of $961.8 million compared to $988.6 million as of Dec. 31, 2025.

Conference Call and Webcast At 8 a.m. EST today, Nov. 3, 2026, Madrigal will host a webcast to review its financial and operating results and provide a general business update. To access the webcast, please visit the investor relations section of the Madrigal website or click here to register. An archived webcast will be available on the Madrigal website following the event.

About MASH Metabolic dysfunction-associated steatohepatitis (MASH) is a serious liver disease that can progress to cirrhosis, liver failure, liver cancer, the need for liver transplantation, and premature mortality. MASH is the leading cause of liver transplantation in women and the second leading cause of all liver transplantation in the U.S. It is the fastest-growing indication for liver transplantation in Europe.

Once patients progress to MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), the risk of adverse liver outcomes increases dramatically: these patients have a 10 to 17 times higher risk of liver-related mortality as compared to patients without fibrosis. Patients with MASH who progress to cirrhosis face a 42 times higher risk of liver-related mortality, underscoring the need to treat MASH before complications of cirrhosis develop. MASH is also an independent driver of cardiovascular disease, the leading cause of mortality for patients.

As disease awareness improves and disease prevalence increases, the number of diagnosed patients with F2 to F4c MASH is growing.

About Madrigal Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.

Forward Looking Statements This press release includes “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended, including statements related to the expected growth of Rezdiffra, expected growth of the MASH market, Madrigal’s leadership position in the MASH sector, the potential benefit of resmetirom in patients with compensated MASH cirrhosis, the expected receipt of data from the MAESTRO-NASH OUTCOMES trial in late 2027, the expected initiation of the MAESTRO-CSPH trial in the first half of 2027, the potential impact of positive results from Madrigal’s outcomes trials, expectations regarding competitor trials and the potential benefit of Madrigal’s pipeline candidates in the treatment of MASH. Forward-looking statements are based on Madrigal’s beliefs and assumptions on information currently available to it and are subject to a number of risks and uncertainties including, but not limited to: the assumptions underlying the forward-looking statements; Madrigal’s ability to successfully commercialize Rezdiffra in the U.S. and Europe; conditions imposed by regulators relating to the scope and design of Madrigal’s clinical trials; risks related to obtaining and maintaining regulatory approvals, including, but not limited to, potential regulatory delays or rejections; Madrigal’s history of operating losses and the possibility that it may never achieve or maintain consistent profitability; risks associated with meeting the objectives of Madrigal’s clinical trials, including, but not limited to the ability to achieve enrollment objectives concerning patient numbers (including an adequate safety database), outcomes objectives and/or timing objectives for Madrigal’s trials; any delays or failures in enrollment, and the occurrence of adverse safety events; risks related to the effects of Rezdiffra’s (resmetirom’s) mechanism of action or of any other product candidate; market demand for and acceptance of Rezdiffra; Madrigal’s ability to service indebtedness and otherwise comply with debt covenants; outcomes or trends from competitors; future topline data timing or results; Madrigal’s ability to prevent and/or mitigate cyber-attacks; Madrigal’s ability to protect its intellectual property rights; the uncertainties inherent in clinical testing; uncertainties concerning analyses or assessments outside of a controlled clinical trial; and changes in laws and regulations applicable to Madrigal’s business and its ability to comply with such laws and regulations. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by applicable law, Madrigal undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Please refer to Madrigal’s reports filed with the U.S. Securities and Exchange Commission (SEC) for more detailed information regarding these risks and uncertainties and other factors that may cause actual results to differ materially from those expressed or implied. Madrigal specifically discusses these risks and uncertainties in greater detail in the sections appearing in Part I, Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2025, and as updated from time to time by Madrigal’s other filings with the SEC.

Madrigal may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Madrigal’s website in addition to following its press releases, filings with the SEC, public conference calls, and webcasts.

Madrigal Pharmaceuticals, Rezdiffra® and associated logos are trademarks of Madrigal Pharmaceuticals, Inc.

Investor Contact Tina Ventura, [email protected]

Media Contact Christopher Frates, [email protected]

(tables follow)

| | | | | | | | |

| Madrigal Pharmaceuticals, Inc. |

| Condensed Consolidated Statement of Operations |

| (in thousands, except share and per share amounts) |

| (unaudited) |

| | | | | | | | |

| | Three Months Ended | | Nine Months Ended |

| | September 30, | | September 30, |

| | 2026 | | 2025 | | 2026 | | 2025 |

| Revenues: | | | | | | | |

| Product revenue, net | $ | 431,268 | | | $ | 287,268 | | | $ | 1,106,857 | | | $ | 637,320 | |

| Operating expenses: | | | | | | | |

| Cost of sales | | 37,815 | | | | 18,122 | | | | 104,669 | | | | 31,700 | |

| Research and development | | 71,755 | | | | 174,004 | | | | 271,625 | | | | 272,257 | |

| Selling, general and administrative | | 265,709 | | | | 209,117 | | | | 823,605 | | | | 573,851 | |

| Total operating expenses (1) | | 375,279 | | | | 401,243 | | | | 1,199,899 | | | | 877,808 | |

| Income (loss) from operations | | 55,989 | | | | (113,975 | ) | | | (93,042 | ) | | | (240,488 | ) |

| Interest income | | 8,239 | | | | 10,308 | | | | 23,586 | | | | 27,905 | |

| Interest expense | | (8,069 | ) | | | (7,451 | ) | | | (23,828 | ) | | | (14,012 | ) |

| Loss on extinguishment of debt | | - | | | | (2,779 | ) | | | - | | | | (2,779 | ) |

| Other expense, net | | (717 | ) | | | (293 | ) | | | (3,604 | ) | | | (335 | ) |

| Net income (loss) | $ | 55,442 | | | $ | (114,190 | ) | | $ | (96,888 | ) | | $ | (229,709 | ) |

| | | | | | | | |

| Net income (loss) per common, Series A preferred and Series B preferred share: | | | | | | | |

| Net income (loss) per common, Series A preferred, and Series B preferred share - basic | $ | 1.90 | | | $ | (4.01 | ) | | $ | (3.32 | ) | | $ | (8.12 | ) |

| Net income (loss) per common, Series A preferred, and Series B preferred share - diluted | $ | 1.83 | | | $ | (4.01 | ) | | $ | (3.32 | ) | | $ | (8.12 | ) |

| Weighted average number of shares outstanding - basic (2) | | 29,247,673 | | | | 28,508,089 | | | | 29,142,570 | | | | 28,276,865 | |

| Weighted average number of shares outstanding - diluted (2) | | 30,313,137 | | | | 28,508,089 | | | | 29,142,570 | | | | 28,276,865 | |

| | | | | | | | |

| (1) Amounts include non-cash stock-based compensation expense as follows: |

| Cost of sales | $ | 138 | | | $ | - | | | $ | 363 | | | $ | - | |

| Research and development | | 8,676 | | | | 6,473 | | | | 23,401 | | | | 17,042 | |

| Selling, general and administrative | | 30,133 | | | | 19,779 | | | | 84,572 | | | | 55,300 | |

| Total stock-based compensation | $ | 38,947 | | | $ | 26,252 | | | $ | 108,336 | | | $ | 72,342 | |

| | | | | | | | |

| (2) Basic weighted average shares outstanding reflect the weighted-average impact of common stock, previously issued pre-funded warrants, previously issued Series A and Series B convertible preferred shares outstanding, and earned PSUs during the period. Diluted weighted average shares outstanding also include the weighted average incremental shares from dilutive stock-based awards and warrants, as applicable. |

| | | | | | | | | | | | | | | | |

| Madrigal Pharmaceuticals, Inc. | |

| Condensed Consolidated Balance Sheets | |

| (in thousands) | |

| (unaudited) | |

| | September 30, | | December 31, |

| | 2026 | | 2025 |

| Cash, cash equivalents, restricted cash and marketable securities | $ | 961,771 | | | $ | 988,649 | |

| Trade receivables, net | | 227,377 | | | | 134,476 | |

| Other current assets | | 197,961 | | | | 122,645 | |

| Other non-current assets | | 47,280 | | | | 13,819 | |

| Total assets | $ | 1,434,389 | | | $ | 1,259,589 | |

| | | | | | |

| Liabilities and Equity | | | | | |

| Current liabilities | $ | 454,244 | | | $ | 310,288 | |

| Long-term liabilities | | 353,204 | | | | 346,612 | |

| Stockholders’ equity | | 626,941 | | | | 602,689 | |

| Total liabilities and stockholders’ equity | $ | 1,434,389 | | | $ | 1,259,589 | |

| | | | | | |

Primary Logo

Source: Madrigal Pharmaceuticals, Inc.

close

You are now leaving madrigalpharma.com.

By clicking this link you will be redirected to a website that is neither owned nor controlled by Madrigal. Madrigal is not responsible for the content or services of this site.

Continue

Stay Here

close

October 27, 2026

PDF Version

  • Rezdiffra® (resmetirom) to be featured in more abstracts than any other approved or investigational MASH therapy

  • Real-world evidence abstracts examine Rezdiffra effectiveness, tolerability and treatment persistence in clinical practice; largest dataset spans more than 12,000 patients

  • Clinical abstracts further characterize the positive effects of Rezdiffra on noninvasive measures of treatment response, cardiovascular risk markers and patient-reported outcomes

CONSHOHOCKEN, Pa., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that new clinical and real-world evidence (RWE) evaluating Rezdiffra and its growing impact on patient care will be presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place Nov. 5-9 in Denver.

Thirteen abstracts will be presented from the company’s RESONANCE program - a scientifically rigorous RWE program generating a comprehensive body of evidence across multiple data sources in MASH, such as natural history data, health systems, electronic health records, insurance claims and pharmacy data. The abstracts at AASLD will examine real-world treatment patterns, monitoring, adherence and persistence among thousands of patients receiving Rezdiffra in routine clinical practice.

“Rezdiffra established a new treatment era in MASH, and as more patients are being diagnosed and treated, real-world evidence is essential to understanding how treatment is working outside the clinical trial setting,” said David Soergel, M.D., Chief Medical Officer of Madrigal. “The breadth of research being presented at AASLD provides a robust and consistent picture of how patients are responding to Rezdiffra in the real world, including improvements in key noninvasive measures of liver health through 12 months. The observations from multiple independent datasets across thousands of treated patients reinforce Rezdiffra as a foundational treatment for MASH, and reflect our commitment to generating rigorous post-approval evidence to advance the field.”

Madrigal Data Presentations at AASLD’s The Liver Meeting 2026

| Title and Abstract # | Presenter |

| Clinical Research Abstracts |

| Early and week 52 biomarker (MRI-PDFF, ALT, MRE and PRO-C3) responses to resmetirom predict improvements in MASH and liver fibrosis *Oral presentation 0010, Clinical Plenary #2 | Rohit Loomba |

| In F0-F3 MASH, ≥5% weight loss (WL) significantly lowers VCTE and ELF independent of biopsy fibrosis improvement; resmetirom (Res) and not placebo (Pbo) reduction of ELF and VCTE are associated with biopsy improvement of fibrosis, independent of WL Poster #2357 | Rohit Loomba |

| Reducing CV risk in patients with MASH independent of baseline based on Lp(a) and LDL lowering by resmetirom Poster #2330 | Meena Bansal |

| Impact of resmetirom on health-related quality of life, work productivity, and disease-specific symptoms in compensated MASH cirrhosis Poster #2266 | Zobair Younossi |

| Treatment with resmetirom improves symptom burden in MASH Poster #3451 | Zobair Younossi |

| Real World Evidence Abstracts |

| Twelve-month changes in laboratory and imaging-based biomarkers following resmetirom initiation: a real-world analysis across cardiometabolic and concomitant medication subgroups *Poster of Distinction #3443 | Anthony Martinez |

| Twelve-month changes in laboratory and imaging-based biomarkers in patients who have initiated resmetirom: a real-world retrospective cohort analysis using electronic health records Poster #3477 | Anthony Martinez |

| Real-world medication adherence and persistence to resmetirom in patients with MASH Poster #2530 | Francis Lobo |

| Leveraging a system level provider-facing fibrosis screening dashboard: signaling the need for a MASH quality measure Poster #2197 | Anna Mageras |

| Real-world characteristics and clinical effectiveness outcomes among MASH patients initiating resmetirom Poster #3481 | Jeevin S. Sandhu |

| Treatment continuity with resmetirom: a real-world study of adherence and persistence in MASH Poster #3514 | Francis Lobo |

| A 12-month real-world assessment of clinical characteristics and biomarker changes following resmetirom initiation in patients with MASH: A descriptive cohort study using electronic medical records in the United States Poster #3516 | Naim Alkhouri |

| Real-world characteristics, treatment patterns, and clinical outcomes among patients with MASH initiating resmetirom Poster #3508 | Meena Bansal |

| Demographic, clinical, and medication use profiles of patients prescribed resmetirom: A US claims-based analysis Poster #3568 | Blake Thomas |

| Treatment persistence among patients prescribed resmetirom in a US claims-based cohort Poster #3559 | Blake Thomas |

| Patient characteristics, treatment patterns, and changes in liver function laboratory tests among resmetirom treated patients in a real-world MASH population Poster #3577 | Nipun Atreja |

| Association of GLP-1 use and end-stage liver disease events in US adults with MASH Poster #3495 | Nipun Atreja |

| Estimating real world clinical and economic implications of GLP-1 persistence and dosing in MASH Poster #3522 | Florencio Calderon |

Rezdiffra (resmetirom) is a once-daily, oral, liver-directed thyroid hormone receptor (THR)-β agonist designed to address key underlying causes of MASH. It was the first medication approved for the treatment of MASH in the U.S. and Europe. In the pivotal Phase 3 MAESTRO-NASH biopsy trial, Rezdiffra achieved both fibrosis improvement and MASH resolution primary endpoints. Rezdiffra also reduced liver stiffness, liver fat, liver enzymes and atherogenic lipids in the MAESTRO-NASH trial and improved health-related quality of life. At one year, 91% of patients treated with Rezdiffra 100mg achieved improvement or stabilization of liver stiffness as measured by vibrational-controlled transient elastography (VCTE), a test that is frequently used to monitor treatment response in clinical practice.

Rezdiffra is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis). Continued approval for this indication may be contingent upon verification and description of clinical benefit in ongoing confirmatory trials. Rezdiffra is not approved in any geography for the treatment of patients with cirrhosis.

About MASH Metabolic dysfunction-associated steatohepatitis (MASH) is a serious liver disease that can progress to cirrhosis, liver failure, liver cancer, the need for liver transplantation and premature mortality. MASH is the leading cause of liver transplantation in women and the second leading cause of all liver transplantation in the U.S., and the fastest-growing indication for liver transplantation in Europe.

Once patients progress to MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), the risk of adverse liver outcomes increases dramatically: these patients have a 10 to 17 times higher risk of liver-related mortality as compared to patients without fibrosis.

Patients with MASH who progress to cirrhosis face a 42 times higher risk of liver-related mortality, underscoring the need to treat MASH before complications of cirrhosis develop. MASH is also an independent driver of cardiovascular disease, the leading cause of mortality for patients.

As disease awareness improves and disease prevalence increases, the number of diagnosed patients F2 to F4c MASH is growing.

About Rezdiffra What is Rezdiffra? Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver.

This indication is approved based on improvement of MASH and liver scarring (fibrosis). There are ongoing studies to confirm the clinical benefit of Rezdiffra.

Before you take Rezdiffra, tell your healthcare provider about all of your medical conditions, including if you:

  • have any liver problems other than MASH.

  • have gallbladder problems or have been told you have gallbladder problems, including gallstones.

  • are pregnant or plan to become pregnant. It is not known if Rezdiffra will harm your unborn baby.

  • A pregnancy safety study for women who take Rezdiffra during pregnancy collects information about the health of you and your baby. You or your healthcare provider can report your pregnancy by visiting https://pregnancyregistry.madrigalpharma.com/ or calling 1-800-905-0324.

  • are breastfeeding or plan to breastfeed. It is not known if Rezdiffra passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take Rezdiffra.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.

  • Rezdiffra and other medicines may affect each other, causing side effects. Rezdiffra may affect the way other medicines work, and other medicines may affect how Rezdiffra works.

  • Especially tell your healthcare provider if you take medicines that contain gemfibrozil to help lower your triglycerides, because Rezdiffra is not recommended in patients taking these medicines.

  • Tell your healthcare provider if you are taking medicines such as clopidogrel to thin your blood or statin medicines to help lower your cholesterol.

  • Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

What are the possible side effects of Rezdiffra? Rezdiffra may cause serious side effects, including:

  • liver injury (hepatotoxicity). Stop taking Rezdiffra and call your healthcare provider right away if you develop the following signs or symptoms of hepatotoxicity: tiredness, nausea, vomiting, fever, rash, your skin or the white part of your eyes turns yellow (jaundice) or stomach pain/tenderness.

  • gallbladder problems. Gallbladder problems such as gallstones, or inflammation of the gallbladder, or inflammation of the pancreas from gallstones can occur with MASH and may occur if you take Rezdiffra. Call your healthcare provider right away if you develop any signs or symptoms of these conditions including nausea, vomiting, fever, or pain in your stomach area (abdomen) that is severe and will not go away. The pain may be felt going from your abdomen to your back and the pain may happen with or without vomiting.

  • The most common side effects of Rezdiffra include: diarrhea, nausea, itching, stomach pain, vomiting, dizziness and constipation.

These are not all the possible side effects of Rezdiffra. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Madrigal at 1-800-905-0324.

Please see the full Prescribing Information, including Patient Information, for Rezdiffra.

About Madrigal Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com and follow us on LinkedIn.

Forward-Looking Statements This press release includes “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended, including statements related to Rezdiffra’s positioning as the foundational therapy in the treatment of MASH and Madrigal’s ability to continue to generate real world evidence for Rezdiffra. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to: the assumptions underlying the forward-looking statements; our ability to successfully commercialize Rezdiffra in the U.S. and Europe; risks related to obtaining and maintaining regulatory approvals, including, but not limited to, potential regulatory delays or rejections; our history of operating losses and the possibility that we may never achieve or maintain profitability; risks associated with meeting the objectives of our clinical trials, including, but not limited to our ability to achieve enrollment objectives concerning patient numbers (including an adequate safety database), outcomes objectives and/or timing objectives for our trials; any delays or failures in enrollment, and the occurrence of adverse safety events; risks related to the effects of Rezdiffra’s (resmetirom’s) mechanism of action or of any other product candidate; market demand for and acceptance of Rezdiffra; our ability to service indebtedness and otherwise comply with debt covenants; outcomes or trends from competitors; future topline data timing or results; our ability to prevent and/or mitigate cyber-attacks; our ability to protect our intellectual property rights; the uncertainties inherent in clinical testing; uncertainties concerning analyses or assessments outside of a controlled clinical trial; and changes in laws and regulations applicable to our business and our ability to comply with such laws and regulations. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Madrigal undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Please refer to Madrigal’s submissions filed with the U.S. Securities and Exchange Commission (SEC) for more detailed information regarding these risks and uncertainties and other factors that may cause actual results to differ materially from those expressed or implied. Madrigal specifically discusses these risks and uncertainties in greater detail in the sections appearing in Part I, Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2025, and as updated from time to time by Madrigal’s other filings with the SEC.

Madrigal may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Madrigal’s website in addition to following its press releases, filings with the SEC, public conference calls, and webcasts.

Madrigal Pharmaceuticals, Rezdiffra**®** and associated logos are trademarks of Madrigal Pharmaceuticals, Inc.

Investor Contact Tina Ventura, [email protected]

Media Contact Krysta Pellegrino, [email protected]

Primary Logo

close

You are now leaving madrigalpharma.com.

By clicking this link you will be redirected to a website that is neither owned nor controlled by Madrigal. Madrigal is not responsible for the content or services of this site.

Continue

Stay Here

close

Prompts

Madrigal Pharmaceuticals, Inc. (ticker MDGL), listed in United States.

Company History

Date Change Detail
Aug 11, 2016 Renamed SYNTA PHARMACEUTICALS CORP → MADRIGAL PHARMACEUTICALS, INC.

ETFs Holding Madrigal Pharmaceuticals, Inc.

ETF Weight in ETF Shares Market value As of
JXX 3.62% 2,065 $ 965.016K Jul 31, 2026
LSEQ short -1.50% -605 $ -258.571K Nov 13, 2026
HRTS 1.46% 1,499 $ 809.505K Aug 31, 2026
GDOC 1.04% 376 $ 203.051K Aug 31, 2026
ILDR 0.89% 6,644 $ 2.817M Nov 16, 2026
FSML 0.77% 1,804 $ 968.658K Jun 30, 2026
FLDZ 0.53% 40 $ 21.478K Jun 30, 2026
RUSC 0.38% 561 $ 301.229K Jun 30, 2026
MKTN short -0.35% -700 $ -375.865K Jun 30, 2026
ESSC 0.31% 238 $ 111.222K Jul 31, 2026
FESM 0.30% 32,841 $ 17.634M Jun 30, 2026
MSSM 0.25% 3,317 $ 1.791M Aug 31, 2026
ESUM 0.17% 680 $ 317.778K Jul 31, 2026
FSCC 0.16% 1,102 $ 595.113K Aug 31, 2026
SEIS 0.16% 1,685 $ 904.761K Jun 30, 2026
FSEG 0.10% 11 $ 5,906.45 Jun 30, 2026
REMC 0.08% 5 $ 2,684.75 Jun 30, 2026
AVIE 0.06% 22 $ 9,327.12 Nov 16, 2026
JSTC 0.02% 162 $ 68.682K Nov 17, 2026
IALT 0.01% 2,303 $ 976.38K Nov 16, 2026